These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21163235)

  • 1. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
    Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
    Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers.
    Burwick RM; Ramsay PP; Haines JL; Hauser SL; Oksenberg JR; Pericak-Vance MA; Schmidt S; Compston A; Sawcer S; Cittadella R; Savettieri G; Quattrone A; Polman CH; Uitdehaag BM; Zwemmer JN; Hawkins CP; Ollier WE; Weatherby S; Enzinger C; Fazekas F; Schmidt H; Schmidt R; Hillert J; Masterman T; Hogh P; Niino M; Kikuchi S; Maciel P; Santos M; Rio ME; Kwiecinski H; Zakrzewska-Pniewska B; Evangelou N; Palace J; Barcellos LF
    Neurology; 2006 May; 66(9):1373-83. PubMed ID: 16682670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.
    De Stefano N; Bartolozzi ML; Nacmias B; Zipoli V; Mortilla M; Guidi L; Siracusa G; Sorbi S; Federico A; Amato MP
    Arch Neurol; 2004 Apr; 61(4):536-40. PubMed ID: 15096402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.
    Carmona O; Masuet C; Alía P; Moral E; Alonso-Magdalena L; Casado V; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2011; 65(3):132-7. PubMed ID: 21325856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
    Lanzillo R; Prinster A; Scarano V; Liuzzi R; Coppola G; Florio C; Salvatore E; Schiavone V; Brunetti A; Muto M; Orefice G; Alfano B; Bonavita V; Brescia Morra V
    J Neurol Sci; 2006 Jun; 245(1-2):141-5. PubMed ID: 16626758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis].
    Guerrero AL; Bueno V; Hernández MT; Martín-Serradilla JI; Carrasco E; Cuadrado I
    Neurologia; 2003 Apr; 18(3):146-8. PubMed ID: 12677480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy.
    van der Walt A; Stankovich J; Bahlo M; Taylor BV; van der Mei IA; Foote SJ; Kilpatrick TJ; Rubio JP; Butzkueven H
    Neurology; 2009 Sep; 73(13):1018-25. PubMed ID: 19786693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of apolipoprotein E genotypes with prognosis in multiple sclerosis.
    Tamam Y; Tasdemir N; Yalman M; Tamam B
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1122-30. PubMed ID: 22165672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship of APOE genetic polymorphism with susceptibility to multiple sclerosis and its clinical phenotypes in Kuwaiti Arab subjects.
    Al-Shammri S; Fatania H; Al-Radwan R; Akanji AO
    Clin Chim Acta; 2005 Jan; 351(1-2):203-7. PubMed ID: 15563891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The absence of a relation between apolipoprotein E genotypes and the severity of multiple sclerosis in Mexican patients].
    Corona T; Guerrero-Camacho JL; Alonso-Vilatela ME; Flores-Rivera Jde J
    Rev Neurol; 2010 Jan 1-15; 50(1):19-22. PubMed ID: 20073019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
    Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E genotype does not influence the progression of multiple sclerosis.
    Savettieri G; Andreoli V; Bonavita S; Cittadella R; Caltagirone C; Fazio MC; Girlanda P; Le Pira F; Liguori M; Logroscino G; Lugaresi A; Nocentini U; Reggio A; Salemi G; Serra P; Tedeschi G; Toma L; Trojano M; Valentino P; Quattrone A
    J Neurol; 2003 Sep; 250(9):1094-8. PubMed ID: 14504972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.